WO1998042386A1 - Preservative composition containing tea tree oil (tto) - Google Patents
Preservative composition containing tea tree oil (tto) Download PDFInfo
- Publication number
- WO1998042386A1 WO1998042386A1 PCT/AU1998/000192 AU9800192W WO9842386A1 WO 1998042386 A1 WO1998042386 A1 WO 1998042386A1 AU 9800192 W AU9800192 W AU 9800192W WO 9842386 A1 WO9842386 A1 WO 9842386A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preservative
- tto
- alcohol
- phenyl substituted
- preservative composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
- A01N65/08—Magnoliopsida [dicotyledons]
- A01N65/28—Myrtaceae [Myrtle family], e.g. teatree or clove
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
Definitions
- PRESERVATIVE COMPOSITION CONTAINING TEA TREE OIL (TTO)" FIELD OF THE INVENTION relates to an improved preservative composition containing tea tree oil which can be utilized in a great range of household, industrial or agricultural products inclusive of personal care products, cosmetics, pharmaceuticals, disinfectants, cleaning preparations, paints and other products which contain a preservative or anti-microbial agent to inhibit spoilage or proliferation of micro-organisms.
- the invention also provides a preservative concentrate which may be incorporated in a vehicle or solvent to form the household, industrial or agricultural product.
- Tea tree oil which is obtained from distillation of Melaleuca alternifolia is known as a natural preservative or having antimicrobial properties.
- TTO Tea tree oil
- Tea tree oil consists of a mixture of monoterpenes, sesquiterpenes and terpene alcohols. Over 90 chemical components have been isolated from tea tree oil. The anti-microbial activity that has been demonstrated with tea tree oil is mainly due to terpinene-4-ol but other components have activity by themselves or contribute synergistically.
- the ISO Standard specifies a minimum of 30% terpinene- 4-ol and a maximum of 15% cineole.
- the cosmetic, pharmaceutical and personal care products which are currently sold on the market usually have a minimum concentration of 0.5% TTO although, in some cases, the pure product is sold.
- Such products utilize TTO for its anti-microbial and solvent properties.
- the range of cosmetic, pharmaceutical and personal care products includes medicated soaps, liquid soaps, deodorants and anti- perspirants, shampoos and conditioners, toothpastes, mouth washes and skin care products inclusive of hand creams, sunscreens and acne preparations.
- TTO can be supplied as a clear aqueous solution in combination with non-ionic surfactants, such as Polysorbate 20 or Tween 20, referred to in the above Priest reference and disodium edetate which is utilized as a chelating agent.
- a hair conditioner formulation including wheat protein amino acids, panthenol which is a nutritional factor, Vitamin E, PEG-7 glyceryl cocoate or Cetiol which is a solubilizer, Dimethicone which is a skin protectant, citric acid, Vitamin A palmitate, butylene glycol as a humectant, cetostearyl alcohol as an emulsifier, cetyl alcohol as emulsion modifier and cetyltrimethyl ammonium chloride as an antiseptic.
- TTO when used in a moisturising cream which may also include cetyl alcohol, disodium edetate, aloe vera gel, a herbal blend of plant extracts, hydrolysed collagen, propylene glycol, butylene glycol, Vitamin E, Vitamin A palmitate, olive oil, jojoba oil, macadamia nut oil, octyl palmitate, and cetearyl glucoside.
- Preservatives such as TTO are useful in that they will prevent or limit proliferation of microbial infection in preparations and, in particular, in aqueous preparations.
- Such preparations may be any pharmaceutical, personal care or cosmetic product. If a preservative is not added to such a product, then microbial contamination could occur and thus present a safety hazard to users of the product or, alternatively, result in spoilage of the product.
- the efficacy of an anti-microbial preservative may be enhanced or diminished by the active constituent of a pharmaceutical, personal care or cosmetic product or by the formulation of the product or by the container or closure which is used for the product.
- the preservative properties of the preparation are adequate if, in the conditions of the test, there is a significant fall, or no increase, as appropriate, in the number of micro-organisms in the inoculated preparation after the prescribed times and temperatures.
- the criteria of acceptance, in terms of decrease in the number of micro-organisms with time, vary for different types of preparations.
- Test organisms usually include Aspergillus niger (ATCC 16404), Candida albicans (ATCC 10231 ), Pseudomonas aeruginosa (ATCC 9027) and Staphylococcus aureus (ATCC 6538).
- the BP is a far more rigorous test than the USP, requiring, for example, a 3 log reduction of bacteria after 48 hours for topical preparations and a 3 log reduction at 14 days for oral preparations compared to the USP which requires that the number of bacteria be reduced to not more than 0.1 % of the initial concentration after 14 days.
- TTO is included in such formulations at a concentration of greater than 2.0%.
- this concentration of TTO in many cases is excessive having regard to the nature of the product as TTO is not only expensive but also has a sharp astringency and strong odour.
- the preservative composition of the invention comprises from 0.10-2.0% TTO, from 0.10-2.0% of a phenyl substituted alcohol and optionally at least 10% water together with other components which may include solvents for TTO and phenyl substituted alcohol inclusive of water and polar organic solvents, such as ethanol, methanol, propylene glycol, butylene glycol, ethylene glycol or other polyhydroxy alkanes.
- Phenyl substituted alcohols include a phenyl group and an alkyl moiety and include within their scope, phenylalkanols and phenoxyalkanols. Phenyl substituted alcohols also dissolve in natural oils, such as olive oil, jojoba oil or macadamia nut oil.
- Preferred phenyl substituted alcohols include phenylethanol, phenoxyethanol and benzyl alcohol.
- Benzyl alcohol is the preferred phenyl substituted alcohol for use in the invention.
- the composition may be in any conventional form suitable for use as household, industrial or agricultural product inclusive of a cosmetic, pharmaceutical product, personal care product, disinfectant, paint, cleaning product or other product requiring a preservative or antimicrobial product to inhibit spoilage or proliferation of micro-organisms.
- the composition may be, for example, in the form of a cream, gel stick, paint, foam, ointment, lotion or spray.
- the composition may also include additives and excipients conventionally found in topical formulations, such as emulsifiers, surfactants inclusive of ionic, non-ionic and amphoteric surfactants, thickening agents, emollients, stabilizers and humectants.
- the composition contains a maximum of 2.0% of both TTO and phenyl substituted alcohol which may be present in equal concentrations of 1.0%. It is even more preferred that the composition contains a maximum of 1.0% of both TTO and phenyl substituted alcohol with, again, TTO and phenyl alcohol being present in equal concentrations of 0.5%. It is also commercially appropriate that the pharmaceutical, personal care or cosmetic composition contains as low an amount of preservative as is possible for reasons of cost as well as market acceptance. TTO, for example, if present in too high a concentration, will provide a distinctive odour and is also relatively expensive. It will be appreciated that TTO may be used in its natural form as well as one or more active components thereof, e.g.
- TTO terpinen-4-ol and/or alpha terpineol.
- TTO terpinen-4-ol
- tea tree oil refers to natural forms of TTO which are obtained from any appropriate Melaleuca species or Leptospermum species, such as, for example, M. alternifolia, M. linariifolia, M. dessitafolia as well as modified extracts thereof including the aforementioned active components per se.
- Benzyl alcohol may be used as it is obtained commercially, such as by the action of sodium or potassium carbonate on benzyl chloride. However, benzyl alcohol may be used as obtained naturally from appropriate sources, such as jasmine, hyacinth, or ylang-ylang oils.
- composition of the invention may be used as a clear aqueous solution which may comprise, in addition to TTO and benzyl alcohol, 1-20% surfactant, emulsifier or solubilizing agent. More preferably a non-ionic surfactant such as POLYSORBATE may be utilized. Other suitable surfactants are also described hereinafter.
- the composition of the invention may include 1-10% of an emollient which moisturizes the skin or, more preferably, 1-5% of the emollient.
- a suitable emollient is CETIOL or PEG 7 glyceryl cocoate.
- a humectant such as glycerol or propylene glycol
- a thickener or viscosity increasing agent such as a gum, in the form of a guar gum, gum tregacanth, xanthan gum, or galactomannan gum.
- a detergent such as sodium lauryl ether sulphate and/or ammonium lauryl sulphate.
- a cleaning agent such as coconut diethanolamide.
- the composition may include waxes, such as 1-5% of cetyl alcohol or stearyl alcohols.
- essential oils such as Vitamin E or Vitamin A
- hydrolysed collagen such as Vitamin E or Vitamin A
- amino acids such as panthenol and other nutritional factors as may be required.
- compositions of the invention when used as a clear aqueous solution are set out hereinbelow.
- clear liquid soap clear liquid soap
- moisturizing cream with collagen and herbal extracts moisturizing cream with collagen and herbal extracts
- a pearlescent shampoo and a hair conditioner are set out hereinbelow.
- TTO 0.5% TTO, 0.5% benzyl alcohol, 3.0% cetostearyl alcohol, 0.15% Dimethicone Vitamin E Natural (Covitol F1300), 0.05% PEG-7 glyceryl cocoate (Cetiol HE), 1.0% wheat protein amino acids (Hydrotriticum WAA), 0.10% citric acid (10.0%), 0.10% panthenol and 1.0% cetyltrimethyl ammonium chloride 50.0% (Dehyquart A) with the balance being purified water.
- a preservative concentrate comprising:- (i) 20-80% TTO;
- the concentrate there is provided 25-80% surfactant and 20-80% dispersing agent. More preferably, there is provided 35-45% surfactant and 20-50% dispersing agent.
- the concentrate comprises 30-50% TTO and 30- 50% phenyl substituted alcohol.
- the surfactant may be an anionic surfactant, such as a carboxylate, sulfonate, sulfated alcohol or sulfated alcohol ethoxylate.
- Cationic and amphoteric surfactants may also be used but the preferred surfactant is a non-ionic surfactant, such as polyoxyethylene surfactant or carboxylic acid esters, such as glycerol esters, polyoxyethylene esters, anhydrosorbitol esters, natural fats, oils and waxes and ethoxylated and glycol esters of fatty acids.
- a non-ionic surfactant such as polyoxyethylene surfactant or carboxylic acid esters, such as glycerol esters, polyoxyethylene esters, anhydrosorbitol esters, natural fats, oils and waxes and ethoxylated and glycol esters of fatty acids.
- Preferred surfactants are marketed under the trade marks ETOCAS or CREMOPHOR.
- the function of the dispersing agent is to facilitate dispersion of the TTO in the concentrate. Without the dispersing agent, it would be necessary to mix TTO very slowly with water together with the phenyl substituted alcohol which necessitates the concentrate forming a gel.
- the use of the dispersing agent may also provide a clear solution of concentrate.
- a preferred dispersing agent is propylene glycol although it will be appreciated that any other polyhydroxy alcohol could be used, such as glycerol, sorbitol or polyethylene glycol. Other alcohols may also be utilized, such as methanol, ethanol or isopropanol.
- a preferred form of concentrate is provided in water soluble form which includes 0.5 g TTO, 0.5 g benzyl alcohol, 1.0 g surfactant and 0.5 g propylene glycol.
- the resulting 2.5 g concentrate may be dissolved in 100 g of vehicle or diluent.
- the concentrate may comprise 0.5 g
- TTO 0.5 g benzyl alcohol and 1.0 g propylene glycol.
- a concentrate which may be dissolved in 100 g of vehicle or diluent. Such a concentrate may be utilized for non-aqueous vehicles or solvents.
- An example of a concentrate produced in accordance with the invention comprises 20% TTO, 20% benzyl alcohol, 35-40% Etocas 35, (i.e. Polyoxyl 35 castor oil) which is used as a surfactant and 20% propylene glycol.
- Etocas 35 i.e. Polyoxyl 35 castor oil
- propylene glycol i.e. Polyoxyl 35 castor oil
- Emulgade 1000 Nl which is a colloid disperse mixture of cetyl stearyl alcohol with non-ionic emulsifiers on the basis of saturated fatty polyglycol esters, 5% arachis oil, 2.5% glycerol and 2.5% preservative concentrate with the balance being purified water.
- the steps associated in preparation of the conditioner involved heating cetyl alcohol and cetostearyl alcohol to 70°C.
- Vantoc CC is dissolved in water and heated to 70°C. The two solutions are added together and stirred and cooled to 40°C at which time CroquotL is added and mixed. The mixture is cooled to 35°C and the DiPanthenol is added with the preservative concentrate. The conditioner is then stirred until cold.
- Candida albicans NCPF 3179 ATCC 10231 , IP 48.72
- Pseudomonas aeruginosa NCIMB 8626 ATCC 9027, CIP
- a tryptone soya agar plate for bacteria or Sabouraud agar plate for fungi Preparatory to the test, inoculate the surface of a tryptone soya agar plate for bacteria or Sabouraud agar plate for fungi, with the recently grown stock culture of each of the specified micro-organisms. Incubate the bacterial cultures at 30-35° for 18-24 hours, the culture of Candida albicans at 20-25° for 48 hours, and the culture of Aspergillus niger at 20-25° for 7 days or until good sporulation is obtained. Subcultures may be needed after revival before the organism is in its optimal state, but it is recommended that the number of sub-cultures be kept to a minimum.
- a sterile suspending fluid containing 0.9% w/v of sodium chloride and 0.1 % of peptone for dispersal and transfer of the surface growth into a suitable vessel. Add sufficient suspending fluid to reduce the microbial count to about 10 8 micro-organisms per ml.
- a sterile suspending fluid containing 0.9% w/v of sodium chloride and 0.05% w/v of Polysorbate 80 and adjust the spore count to about 10 8 per ml by adding the same solution.
- the volume of the suspension of inoculum does not exceed 1 % of the volume of the product. Mix thoroughly to ensure homogeneous distribution.
- the USP preservative efficacy test is carried out by a similar procedure as described above in relation to the BP preservative efficacy test.
- preparations to pass the USP must show (i) a reduction in growth in relation to bacteria at not more than 0.1 % of initial concentrations after 14 days and (ii) in relation to fungi, there must be shown that during the first 14 days, the concentration must remain at or below the initial concentration. In these situations, it is also necessary to demonstrate the concentrations of each test organism must remain at or below the levels referred to in (i) and (ii) above for the rest of a 28 day test period.
- Example 3 A similar preparation was made as described in Example 1 with the concentration of benzyl alcohol being increased to 0.5%. The results are shown in TABLE 2 and it will be noted that this preparation passed both the BP and the USP. Example 3
- Example 4 A similar preparation was made as described in Example 1 with the concentration of TTO being decreased to 0.3%. The results are shown in TABLE 3 and it will be noted that this preparation did not pass either the BP or USP. Example 4
- Example 4 A similar preparation was made as described in Example 1 with the exception that the concentration of benzyl alcohol was increased to 0.5% and the concentration of TTO was decreased to 0.3%. The results are shown in TABLE 4 and it will be noted that this preparation passed both the BP and USP.
- Example 5 A similar preparation was made as described in Example 1 with the exception that TTO was omitted and benzyl alcohol included in a concentration of 0.5%. The results are shown in TABLE 5 and it will be noted that this preparation did not pass either the BP and USP.
- the fungal counts were not reduced by a factor of 10 2 within 14 days.
- Example 7 A similar preparation was made as described in Example 1 with the exception that benzyl alcohol was omitted and TTO had a concentration of 0.5%. The results are shown in TABLE 7 and it will be noted that this preparation did not pass both the BP for topical preparations because the Aspergillus niger count was not reduced by a factor of 10 2 within 14 days.
- Example 8 A preparation comprising 0.3% TTO in aqueous solution with 1.0% Etocas 35 was tested in relation to both the BP and USP. It will be noted in TABLE 8 that this preparation did not pass either the BP and USP and, in particular, was relatively inactive against Pseudomonas aeruginosa and Aspergillus niger.
- Example 9 A preparation comprising 0.3% TTO in aqueous solution with 1.0% Etocas 35 was tested in relation to both the BP and USP. It will be noted in TABLE 8 that this preparation did not pass either the BP and USP and, in particular, was relatively inactive against Pseudomonas aeruginosa and Aspergillus niger.
- Example 9 A preparation comprising 0.3% TTO in aqueous solution with 1.0% Etocas 35 was tested in relation to both the BP and USP. It will be noted in TABLE 8 that this preparation did not pass either the BP and USP and, in particular, was relatively inactive against P
- a preparation comprising 0.2% benzyl alcohol, 1 % Etocas 35, 0.5% propylene glycol and the remainder being water, was prepared and tested in relation to the BP topical criteria having regard to Aspergillus niger alone. The results are shown in TABLE 9 and it will be noted that this preparation did not pass the BP. The preparation was also tested in regard to the USP having regard to Aspergillus niger alone and the results are shown in TABLE 10. It will be noted that this preparation did not pass the USP.
- Example 10 The preparation of Example 9 was modified to increase the benzyl alcohol concentration alone to 0.5% and tested in relation to the BP in relation to having regard to Aspergillus niger alone. It is noted in TABLE 11 that there was a marked improvement in effectiveness against Aspergillus niger and thus this preparation passed the BP.
- Example 11
- Example 10 was repeated in its entirety and tested against the USP criteria and the results shown in TABLE 12 show that similar results were obtained to those in Example 10.
- Example 12 The preparation of Example 9 was modified so as to have a concentration of 1.0% of benzyl alcohol and tested against both the BP topical criteria in relation to Aspergillus niger alone and the USP criteria. These results are shown in TABLES 13 and 14 respectively and indicate that benzyl alcohol has a strong inhibitory effect on growth of Aspergillus niger.
- Example 14 A similar preparation was made as described in Example 13 with the concentration of phenoxyethanol being increased to 0.5%. The results shown in TABLE 16 indicate that this preparation passed both the BP (criteria A) and the USP.
- Example 18 A similar preparation was made as described in Example 13 with the exception that phenyoxyethanol was increased to 1.0% and TTO was omitted. The results as shown in TABLE 20 indicate that the preparation passed the requirements of the BP (criteria A) and the USP.
- Example 20 A similar preparation was made as described in Example 13 with the exception that phenyoxyethanol was increased to 1.0% and TTO and Etocas 35 were omitted. The results as shown in TABLE 22 indicate that the preparation passed both the requirements of BP (criteria A) and the USP.
- Example 21
- Example 22 A similar preparation was made as described in Example 21 with the exception that phenoxyethanol was increased to 0.5%. The results as shown in TABLE 24 indicate that the preparation passed both the requirements of the BP and the USP.
- Example 23
- Example 24 A similar preparation was made as described in Example 21 with the exception that TTO was reduced to 0.3%. The results as shown in TABLE 25 indicate that the preparation did not pass the requirements of the BP and the USP for Aspergillus niger.
- Example 24
- Example 25 A similar preparation was made as described in Example 21 with the exception that phenoxyethylene was increased to 0.5% and TTO was decreased to 0.3%. The results as shown in TABLE 26 indicate that the preparation passed both the requirements of the BP and the USP.
- Example 25
- Example 26 A similar preparation was made as described in Example 21 with the exception that phenoxyethanol was increased to 0.5% and TTO was omitted. The results as shown in TABLE 27 indicate that the preparation failed both the requirements of the BP and the USP.
- Example 26
- Example 27 A similar preparation was made as described in Example 21 with the exception that phenoxyethanol was increased to 1.0% and TTO was omitted. The results as shown in TABLE 28 indicate that the preparation passed both the requirements of the BP and the USP.
- Example 27
- Example 28 A similar preparation was made as described in Example 21 with the exception that phenoxyethanol was increased to 0.5% and TTO and Etocas 35 were omitted. The results as shown in TABLE 29 indicate that the preparation passed both the requirements of the BP and the USP.
- Example 28
- the preferred preservatives of the composition contain at least 0.3% TTO and 0.5% benzyl alcohol. It is also noted that benzyl alcohol is more inhibitory towards growth of Aspergillus niger which is relatively unaffected by TTO. TTO, on the other hand, is more effective against bacteria, including Pseudomonas aeruginosa, which is relatively unaffected by benzyl alcohol.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Paints Or Removers (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54453998A JP2001517236A (en) | 1997-03-24 | 1998-03-24 | Preservation composition containing tea tree oil (TTO) |
AU63861/98A AU6386198A (en) | 1997-03-24 | 1998-03-24 | Preservative composition containing tea tree oil (tto) |
CA 2284711 CA2284711A1 (en) | 1997-03-24 | 1998-03-24 | Preservative composition containing tea tree oil (tto) |
EP98909224A EP0983092A1 (en) | 1997-03-24 | 1998-03-24 | Preservative composition containing tea tree oil (tto) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO5835A AUPO583597A0 (en) | 1997-03-24 | 1997-03-24 | Preservative composition containing tea tree oil |
AUPO5835 | 1997-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998042386A1 true WO1998042386A1 (en) | 1998-10-01 |
Family
ID=3800138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1998/000192 WO1998042386A1 (en) | 1997-03-24 | 1998-03-24 | Preservative composition containing tea tree oil (tto) |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0983092A1 (en) |
JP (1) | JP2001517236A (en) |
CN (1) | CN1257432A (en) |
AU (1) | AUPO583597A0 (en) |
CA (1) | CA2284711A1 (en) |
WO (1) | WO1998042386A1 (en) |
ZA (1) | ZA982456B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1126759A1 (en) | 1998-11-06 | 2001-08-29 | Coast Biologicals Limited | Antimicrobial composition comprising leptospermum scoparium) and melaleuca alternifolia oils |
WO2002015864A2 (en) * | 2000-08-25 | 2002-02-28 | Unilever Plc | A vehicle and concentrates for customized personal care products |
WO2003045340A1 (en) * | 2001-11-27 | 2003-06-05 | Unilever Plc | Hair treatment compositions |
WO2015124943A1 (en) * | 2014-02-20 | 2015-08-27 | HART, Deborah Mary | Cleaning composition |
EP2475432B1 (en) | 2009-09-10 | 2018-06-06 | Dalli-Werke GmbH & Co. KG | Cosmetic spray formulation with antimicrobial effect |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100459972C (en) * | 2006-11-07 | 2009-02-11 | 华南农业大学 | Anti-acne moisturizing cream and preparation process thereof |
JP2009161585A (en) * | 2007-12-28 | 2009-07-23 | Yushiro Chem Ind Co Ltd | Water-soluble metal working fluid composition |
EA201291222A1 (en) * | 2010-05-05 | 2013-04-30 | Биомор Израэл Лтд. | COMBINATIONS OF FUNGICIDAL CONNECTIONS AND OIL OF TEA TREE |
CN105358125B (en) * | 2013-06-28 | 2018-07-06 | 隆萨有限公司 | Cooperate with preservative blends |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009890A (en) * | 1987-08-10 | 1991-04-23 | Trilling Medical Technologies, Inc. | Burn treatment product |
US5096709A (en) * | 1988-05-09 | 1992-03-17 | Melaleuca, Inc. | Muscle relaxant and analgesic containing oil of Melaleuca, spp. |
WO1992006700A1 (en) * | 1990-10-22 | 1992-04-30 | Mankovitz Roy J | Topical preparation and method for suppression of skin eruptions caused by herpes simplex virus |
-
1997
- 1997-03-24 AU AUPO5835A patent/AUPO583597A0/en not_active Abandoned
-
1998
- 1998-03-23 ZA ZA982456A patent/ZA982456B/en unknown
- 1998-03-24 CA CA 2284711 patent/CA2284711A1/en not_active Abandoned
- 1998-03-24 WO PCT/AU1998/000192 patent/WO1998042386A1/en not_active Application Discontinuation
- 1998-03-24 EP EP98909224A patent/EP0983092A1/en not_active Withdrawn
- 1998-03-24 JP JP54453998A patent/JP2001517236A/en not_active Ceased
- 1998-03-24 CN CN98805398A patent/CN1257432A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5009890A (en) * | 1987-08-10 | 1991-04-23 | Trilling Medical Technologies, Inc. | Burn treatment product |
US5096709A (en) * | 1988-05-09 | 1992-03-17 | Melaleuca, Inc. | Muscle relaxant and analgesic containing oil of Melaleuca, spp. |
WO1992006700A1 (en) * | 1990-10-22 | 1992-04-30 | Mankovitz Roy J | Topical preparation and method for suppression of skin eruptions caused by herpes simplex virus |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1126759A1 (en) | 1998-11-06 | 2001-08-29 | Coast Biologicals Limited | Antimicrobial composition comprising leptospermum scoparium) and melaleuca alternifolia oils |
EP1126759A4 (en) * | 1998-11-06 | 2002-04-24 | Coast Biolog Ltd | Antimicrobial composition comprising leptospermum scoparium) and melaleuca alternifolia oils |
US6514539B1 (en) | 1998-11-06 | 2003-02-04 | Coast Biologicals Limited | Antimicrobial composition comprising Leptospermum scoparium and Melaleuca alternifolia oils |
AU768249B2 (en) * | 1998-11-06 | 2003-12-04 | Coast Biologicals Limited | Antimicrobial composition comprising Leptospermum scoparium and Melaleuca alternifolia oils |
WO2002015864A2 (en) * | 2000-08-25 | 2002-02-28 | Unilever Plc | A vehicle and concentrates for customized personal care products |
WO2002015864A3 (en) * | 2000-08-25 | 2002-09-19 | Unilever Plc | A vehicle and concentrates for customized personal care products |
WO2003045340A1 (en) * | 2001-11-27 | 2003-06-05 | Unilever Plc | Hair treatment compositions |
EP2475432B1 (en) | 2009-09-10 | 2018-06-06 | Dalli-Werke GmbH & Co. KG | Cosmetic spray formulation with antimicrobial effect |
WO2015124943A1 (en) * | 2014-02-20 | 2015-08-27 | HART, Deborah Mary | Cleaning composition |
Also Published As
Publication number | Publication date |
---|---|
CN1257432A (en) | 2000-06-21 |
AUPO583597A0 (en) | 1997-04-24 |
ZA982456B (en) | 1998-09-23 |
CA2284711A1 (en) | 1998-10-01 |
JP2001517236A (en) | 2001-10-02 |
EP0983092A1 (en) | 2000-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4966754A (en) | Preservation of cosmetic compositions | |
JP4418976B2 (en) | Antiseptic disinfectant and cosmetic composition | |
US8741271B2 (en) | Antimicrobial compositions containing essential oils | |
WO2004028519A1 (en) | Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides | |
EP2316410A2 (en) | Composition based on glycerol ether/polyol mixtures | |
EP0535789A2 (en) | Topical cleansing and conditioning composition | |
JP2003081761A (en) | Emulsified composition | |
CN102573851A (en) | Broad spectrum preservation blends | |
CN111727076A (en) | Disinfecting compositions and methods of making and using the same | |
US6475991B2 (en) | Use of α-alkylglucosides and α-alkylglucoside esters as anti-microbial an agents | |
KR102456647B1 (en) | A preservative comprising caprylhydroxamic acid, 4'-hydroxyacetophenone, and polyol for skin external application, and a cosmetic composition comprising the same | |
WO2019002391A1 (en) | Antimicrobial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and an organic acid compound, and cosmetic composition containing same | |
JP2017025005A (en) | Antiseptic agent containing emblica officinalis | |
US20010018060A1 (en) | Use of particular fatty substances which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter | |
EP0983092A1 (en) | Preservative composition containing tea tree oil (tto) | |
KR20120103399A (en) | Antibacterial or preservative composition containing 3-butoxy-1,2-propanediol | |
CN115397522B (en) | Composition comprising preservative of natural origin | |
JP5072930B2 (en) | Antiseptic disinfectant and cosmetic composition | |
JP2007161654A (en) | Antiseptic microbicide, cosmetic or medicine comprising the same antiseptic microbicide formulated therein and antiseptic microbicidal method | |
AU6386198A (en) | Preservative composition containing tea tree oil (tto) | |
CN110831570B (en) | New use | |
KR20030026065A (en) | Preservation agent containing 2-ethyl-1,3-hexanediol and composition for external application comprising the preservation agent | |
JP2941241B2 (en) | Preservatives and cosmetic or pharmaceutical compositions containing them | |
JPH11302147A (en) | Cosmetic | |
JPH10203991A (en) | Preparation for external use for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98805398.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1998 544539 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2284711 Country of ref document: CA Ref document number: 2284711 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09401317 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 63861/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 500179 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998909224 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998909224 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998909224 Country of ref document: EP |